Kibur Medical Presents a Rational Approach to Identify Novel Combinations as Potential Immuno-oncology Therapies at the American Academy of Cancer Research in Orlando, FL
BOSTON (PRWEB) April 06, 2023 -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present two posters at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing immune-oncology applications of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.
The first poster #5806, in collaboration with commercial partner Charles River Laboratories, titled “Transcriptomic Analysis in a Renal Cancer PDX Model Enables the Deconvolution of Additive and Synergistic Effects of the Six Different Standard of Care Compounds with Anti-PD-1 Treatment”, will be presented on April 18th from 1:30 p.m. - 5:00 p.m.
The second and related poster #4916 from the Jonas Lab at the Brigham & Women’s Hospital (Boston) and in collaboration with Gordon Mills, Lisa M. Coussens and Joe W. Gray from the Oregon Health & Science University is titled “Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer”, will be presented on April 18 from 1:30PM – 5:00PM.
“We are excited to present our recent data at AACR this year which demonstrates that our technology can analyze multiple chemotherapies in a variety of tumor models in combination.“ said Professor Oliver Jonas, Kibur’s Scientific Founder. “This work furthers our mission to transform cancer care and advance precision medicine for better patient outcomes.”
In addition to the poster presentations, Kibur Medical will be available to further discuss their technology and how it may be incorporated into a variety of cancer models and applications at Booth #2242.
Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.
About Kibur Medical
Kibur Medical intends to fundamentally disrupt oncology drug development and patient treatment outcomes by application of a validated and proprietary, in vivo pathology-driven technology that brings the laboratory to the patient that allows drug developers to accelerate and de-risk their development programs and clinicians to prescribe with evidence-based medicine the right drug to the right patient for better patient outcomes. Visit our website at https://kiburmed.com to learn more.
Contact:
Jennifer M Rossi, PhD
CEO, Operation-All.com
+1.617.203.6103 ###
Jennifer Rossi, Colin Brenan, http://www.kiburmed.com, 1 6174489086, [email protected]
Share this article